Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth ...

Pfizer has signed a deal to purchase Metsera Inc., an obesity drugmaker in the development stage, after winning a bidding war ...

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per ...

BridgeBio said Pfizer’s filing of a complaint with the NAD “is an attempt to bypass the FDA, the federal agency responsible for overseeing prescription drug advertising, and to challenge promotional ...

Pfizer raised its 2025 profit forecast for the second time this year, as ongoing cost cuts helped make up for slow sales ...

The heated bidding war between Pfizer PFE and Danish rival, Novo Nordisk NVO, related to the proposed acquisition of obesity ...

Revised transaction values Metsera at up to $86.25 per share -- Metsera's Board of Directors unanimously recommends that Metsera stockholders approve the adoption of the amended Pfizer merger ...

Pfizer offers a 7% dividend yield, lower COVID sales, oncology and cardiometabolic focus, and growth from Metsera and ...

Pfizer reported a drop in third-quarter profits Tuesday as lower sales of Covid-19 products more than offset gains in other medications.

During a press conference to announce a drug price deal for GLP-1s, President Donald Trump asked for more details about the ...

Pfizer (NYSE: PFE) beat earnings expectations decisively this morning, posting adjusted EPS of $0.87 against a $0.64 ...

Pfizer (PFE) offers potential 20-30% upside despite revenue risks. Explore its valuation, pipeline prospects, and dividend stability. Click here to read.